• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ispire Technology Inc. Reports Financial Results for Fiscal Third Quarter 2026

    5/7/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ISPR alert in real time by email

    Cash Increased Sequentially by $468,000 to $18 Million

    Plans to Achieve Cash Flow Positive in Second Half of Calendar Year 2026

    Business Stabilized Following Strategic Repositioning

    Phased Roadmap Targets Billions in Addressable Market, Including ~$73B Global Vape, ~$50–70B U.S. Flavored Vape, and $24B+ Global G-Mesh Glass Technology

    LOS ANGELES, May 7, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the third quarter of fiscal 2026, for the three months ended March 31, 2026.

    Ispire

    Michael Wang, Co-Chief Executive Officer of Ispire, commented, "This quarter reflects the successful stabilization of our business and with cash growing sequentially by $468,000 to $18 million, we are now executing against a phased roadmap, with near-term revenue drivers already in production and transformative technology opportunities on the horizon:

    • Our Malaysia manufacturing is live today, giving us a 25% tariff advantage over China in a ~$73B global vape market.
      • Supply of nicotine pouches to global customers commenced in April 2026.
    • Vapor ODM launches in July 2026 for mid-sized brands, with large brand partnerships targeted for 2027.
    • Looking further ahead (2027 and beyond):
      • Age-gating technology through IKE Tech has the potential to unlock the ~$50–70B US flavored vape market
      • G-Mesh glass technology is already drawing interest from big tobacco in a $24B+ legal global market.

    "With cash generation this quarter and proprietary technologies in age-gating and G-Mesh that no competitor can replicate, we have multiple shots on goal across billion-dollar markets, and we believe Ispire is uniquely positioned to deliver outsized value for shareholders."

    Multiple Growth Catalysts, Each Backed by a Massive Addressable Market

    Catalyst

    Timeline

    Opportunity

    Malaysia

    Manufacturing

    Now

    ~$73B global vape market; 25% tariff advantage over

    China

    Vapor ODM

    July 2026 /

    2027

    Mid-sized brands in 2026; large brand partnerships in

    2027

    Age-Gating (IKE

    Tech)

    2027+

    ~$50-70B US flavored vape market currently locked;

    ~6B devices/year US TAM

    G-Mesh Technology

    2027+

    $24B+ legal global vape market; licensing discussions

    with big tobacco underway

    Financial Results for the Fiscal Third Quarter Ended March 31, 2026

    • Revenue was $18.7 million, compared to $26.2 million in the third quarter of fiscal 2025 and $20.3 million in the prior sequential quarter. The sequential decline of $1.6 million, or 8%, represents the smallest second-to-third quarter decline in the Company's history, reflecting the typical seasonal impact of Chinese New Year-related factory shutdowns. The year-over-year decline reflects the Company's continued strategic shift away from lower-quality cannabis revenue toward regulated nicotine delivery and compliance technologies. Overall, the business continues to stabilize.
    • Gross profit of $2.0 million compared to $4.8 million for the third quarter of fiscal 2025 and $3.5 million in the prior sequential quarter. Gross margin was impacted by approximately $2.2 million in one-time product returns from legacy cannabis customers with whom the Company has ceased doing business. Gross margin of 10.7% compared to 18.2% for the third quarter of fiscal 2025, is primarily attributable to the approximately $2.2 million one-time product returns from legacy cannabis customers with whom the Company has ceased doing business.
    • Total operating expenses excluding bad debt expense of $5.9 million, a 36% reduction when compared to operating expenses of $9.3 million for the third quarter of fiscal 2025, and a 3.7% reduction when compared to operating expenses of $6.1 million in the prior sequential quarter. Bad debt expense was $5.6 million, which is $0.5 million less than the third quarter of fiscal 2025 and $1.4 million more than the prior quarter.
    • Net loss of $9.5 million or ($0.17) per share, a 12.3% decrease, compared to net loss of $10.9 million, or ($0.19) per share, in the third quarter of fiscal 2025, and a 44.4% increase compared a net loss of $6.6 million in the prior sequential quarter.
    • Cash: At March 31, 2026, the Company held cash of $18.0 million and working capital of $0.9 million.

    Conference Call

    The Company will conduct a conference call at 8 am ET on Friday, May 7, 2026, to discuss the results, followed by a Q&A session.

    To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call."

    • Date: Thursday, May 7, 2026
    • Time: 8:00 am ET 
    • Dial-In Numbers: United States 844-826-3033 or International + 1-412-317-5185

    This conference call will be webcast live and can be accessed by all interested parties at  https://viavid.webcasts.com/starthere.jsp?ei=1761477&tp_key=3958311007

    Please access the link at least fifteen minutes prior to the start of the call to register, download, and install any necessary audio software.

    A playback will be available until 11:59 pm ET on Friday, May 21, 2026. To listen, please dial 1-844-512-2921 or 1-412-317-6671. Use the passcode 10208863 to access the replay.

    About Ispire Technology Inc.

    Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company's operating subsidiaries own or license more than 400 patents worldwide. Ispire's branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People's Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company's cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information visit www.ispiretechnology.com or follow Inspire on Instagram, LinkedIn, Twitter and YouTube.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act") as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company's actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: whether the Company may be successful in re-entering the U.S. ENDS market; the approval or rejection of any PMTA submitted by the Company; whether the Company will be successful in its plans to further expand into the African market; whether the Company's joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the "Joint Venture") may be successful in achieving its goals as currently contemplated, with different terms, or at all; the Joint Venture's ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company's ability to collect its accounts receivable in a timely manner; the Company's business strategies; the ability of the Company to market to the Ispire ONE™; Ispire ONE™'s success in meeting its goals; the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of its products on the markets; the Ispire ONE™ proving to be safe; and the risk and uncertainties described in "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Cautionary Note on Forward-Looking Statements" and the additional risk described in Ispire's Annual Report on Form 10-K for the year ended June 30, 2025 and any subsequent filings which Ispire makes with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

    Contact:

    HAYDEN IR:

    James Carbonara

    (646)-755-7412

    james@haydenir.com

    Brett Maas

    (646) 536-7331

    brett@haydenir.com

    -- Tables Follow –

     

    ISPIRE TECHNOLOGY INC.

    UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

    (In $USD, except share and per share data)











    March 31,

    2026





    June 30,

    2025



    Assets













    Current assets:













    Cash



    $

    18,033,652





    $

    24,351,765



    Restricted cash





    50,000







    -



    Accounts receivable, net





    28,651,558







    39,664,145



    Inventories





    5,480,044







    6,647,970



    Prepaid expenses and other current assets





    3,523,741







    2,244,505



    Total current assets





    55,738,995







    72,908,385



    Non-current assets:

















    Accounts receivable, net of current portion





    -







    7,367,158



    Property, plant and equipment, net





    2,665,534







    2,952,800



    Intangible assets, net





    2,601,408







    2,232,620



    Right-of-use assets – operating leases





    3,855,373







    5,030,005



    Other investment





    2,000,000







    2,000,000



    Equity method investment





    8,839,130







    9,515,546



    Other non-current assets





    210,617







    210,617



    Total non-current assets





    20,172,062







    29,308,746



    Total assets



    $

    75,911,057





    $

    102,217,131



    Liabilities and stockholders' (deficit)/equity

















    Current liabilities

















    Accounts payable



    $

    5,005,033





    $

    4,172,476



    Accounts payable – related party





    38,159,288







    52,420,256



    Contract liabilities





    3,043,470







    4,861,250



    Accrued liabilities and other payables





    6,003,509







    8,099,991



    Borrowing – current portion





    1,092,052







    1,146,766



    Operating lease liabilities – current portion





    1,546,770







    1,838,815



    Total current liabilities





    54,850,122







    72,539,554





















    Non-current liabilities:

















    Amount due to a related party





    35,000,000







    25,000,000



    Borrowing – net of current portion





    -







    805,361



    Operating lease liabilities – net of current portion





    2,265,347







    3,267,522



    Total non-current liabilities





    37,265,347







    29,072,883



    Total liabilities





    92,115,469







    101,612,437





















    Commitments and contingencies



































    Stockholders' (deficit)/equity:

















    Common stock, par value $0.0001 per share; 140,000,000 shares authorized;

         57,399,396 and 57,193,734 shares issued and outstanding as of March 31, 2026

         and June 30, 2025





    5,740







    5,719



    Treasury stock, at cost





    (60,488)







    (60,488)



    Additional paid-in capital





    51,541,046







    48,833,601



    Accumulated deficit





    (67,450,024)







    (48,065,267)



    Accumulated other comprehensive loss





    (240,686)







    (108,871)



    Total stockholders' (deficit)/equity





    (16,204,412)







    604,694



    Total liabilities and stockholders' (deficit)/equity



    $

    75,911,057





    $

    102,217,131



     

    ISPIRE TECHNOLOGY INC.

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND

    COMPREHENSIVE LOSS

    (In $USD, except share and per share data)







    Three Months Ended

    March 31,





    Nine Months Ended

    March 31,







    2026





    2025





    2026





    2025





























    Revenue



    $

    18,685,501





    $

    26,190,725





    $

    69,322,941





    $

    107,356,898





































    Cost of revenue





    16,694,576







    21,414,820







    58,710,643







    87,184,044





































    Gross profit





    1,990,925







    4,775,905







    10,612,298







    20,172,854





































    Operating expenses:

































    Sales and marketing expenses





    1,091,907







    1,656,527







    4,133,079







    6,710,438



    Credit loss expenses





    5,564,497







    6,103,688







    11,537,950







    13,389,767



    General and administrative expenses





    4,818,256







    7,601,131







    13,995,180







    23,281,014





































    Total Operating expenses





    11,474,660







    15,361,346







    29,666,209







    43,381,219





































    Loss from operations





    (9,483,735)







    (10,585,441)







    (19,053,911)







    (23,208,365)





































    Other income (expense):

































    Interest income





    52,971







    3,480







    253,365







    63,321



    Interest expense





    (87,215)







    (35,646)







    (299,582)







    (60,183)



    Exchange (loss) gain, net





    (30,294)







    24,341







    269,745







    (103,247)



    Other income (expense), net





    202,697







    (86,239)







    215,688







    (47,906)





































    Total Other income (expense), net





    138,159







    (94,064)







    439,216







    (148,015)





































    Loss before income taxes





    (9,345,576)







    (10,679,505)







    (18,614,695)







    (23,356,380)





































    Income taxes





    (177,407)







    (176,990)







    (770,062)







    (1,093,774)





































    Net loss



    $

    (9,522,983)





    $

    (10,856,495)





    $

    (19,384,757)





    $

    (24,450,154)





































    Other comprehensive loss

































    Foreign currency translation adjustments





    (10,490)







    (2,860)







    (131,815)







    (84,327)



    Comprehensive loss



    $

    (9,533,473)





    $

    (10,859,355)





    $

    (19,516,572)





    $

    (24,534,481)





































    Net loss per share

































    Basic and diluted



    $

    (0.17)





    $

    (0.19)





    $

    (0.34)





    $

    (0.43)





































    Weighted average shares outstanding:

































    Basic and diluted





    57,293,826







    57,003,488







    57,269,726







    56,752,454



     

    ISPIRE TECHNOLOGY INC.

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (In $USD, except share and per share data)







    Nine Months Ended

    March 31,







    2026





    2025

















    Net loss



    $

    (19,384,757)





    $

    (24,450,154)



    Adjustments to reconcile net loss to net cash (used in)/provided by operating activities:

















    Depreciation and amortization





    691,894







    592,280



    Credit loss expenses





    11,537,950







    13,389,767



    Right-of-use assets amortization





    1,172,118







    1,001,101



    Stock-based compensation expenses





    2,752,467







    4,923,751



    Inventory impairment





    2,386,751







    73,692



    Loss from equity method investment





    676,416







    407,028



    Debt issuance cost amortization





    96,937







    -



    Changes in operating assets and liabilities:

















    Accounts receivable





    6,841,795







    (14,080,837)



    Inventories





    (1,218,825)







    (1,485,433)



    Prepaid expenses and other current assets





    (1,332,448)







    (715,969)



    Accounts payable and accounts payable – related party





    (3,428,411)







    10,962,439



    Contract liabilities





    (1,817,780)







    (756,872)



    Accrued liabilities and other payables





    (876,774)







    (969,068)



    Operating lease liabilities





    (1,291,706)







    (961,244)



    Net cash used in operating activities





    (3,194,373)







    (12,069,519)





















    Cash flows from investing activities:

















    Purchase of property, plant and equipment





    (324,225)







    (140,956)



    Capitalized costs for patents





    (449,191)







    (781,254)



    Investment in joint venture





    (1,298,311)







    (767,285)



    Net cash used in investing activities





    (2,071,727)







    (1,689,495)





















    Cash flows from financing activities:

















    Common stock repurchase





    (45,001)







    (60,488)



    Proceeds from long term debt





    -







    2,339,362



    Repayment of borrowing





    (957,012)







    -



    Net cash (used in)/provided by financing activities





    (1,002,013)







    2,278,874





















    Net decrease in cash





    (6,268,113)







    (11,480,140)



    Cash – beginning of period





    24,351,765







    35,071,294



    Cash and restricted cash– end of period



    $

    18,083,652





    $

    23,591,154



    Reconciliation of cash and restricted cash

















    Cash





    18,033,652







    23,518,560



    Restricted cash





    50,000







    72,594



    Total cash and restricted cash



    $

    18,083,652





    $

    23,591,154



    Supplemental non-cash investing and financing activities

















    Reclassification of accounts receivable – noncurrent to accounts receivable



    $

    6,934,364





    $

    -



    Reclassification of accounts payable – related party to amount due to a related party



    $

    10,000,000





    $

    -



    Leased assets obtained in exchange for operating lease liabilities



    $

    -





    $

    2,771,082



    Unpaid long term investment in accrued liabilities and other payables



    $

    -





    $

    8,232,715



    Supplemental disclosures

















    Cash paid for income taxes



    $

    1,614,273





    $

    1,413,533



    Cash paid for interest



    $

    299,582





    $

    60,183



     

    ISPIRE TECHNOLOGY INC.

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (In $USD, except share and per share data)





    Three Months Ended



    March 31,



    2026





    2025

    Net loss

    $     (9,522,983)





    $       (10,856,495)

    Adjustments to reconcile net loss to net cash -used in/provided by operating

    activities:

    $                       -





    $                           -

    Depreciation and amortization

    $           210,652





    $               198,955

    Credit loss expenses

    $        5,564,497





    $            6,103,688

    Right-of-use assets amortization

    $           479,982





    $               371,717

    Stock-based compensation expenses

    $           992,478





    $            1,470,877

    Inventory impairment

    $           849,313





    $                          -

    Loss from equity method investment

    $           290,083





    $               230,360

    Debt issuance cost amortization

    $             32,312





    $                          -

    Changes in operating assets and liabilities:

    $                      -





    $                           -

    Accounts receivable

    $        3,662,298





    $            1,170,940

    Inventories

    $     (1,291,943)





    $               181,075

    Prepaid expenses and other current assets

    $        (363,641)





    $               139,686

    Accounts payable and accounts payable – related party

    $        3,582,462





    $         (9,743,313)

    Contract liabilities

    $     (1,927,665)





    $            (549,992)

    Accrued liabilities and other payables

    $          (99,500)





    $            (838,174)

    Operating lease liabilities

    $        (489,737)





    $            (376,953)

    Income tax payable

    $          (12,590)





    $                           -

    Net cash provided by operating activities

    $        1,956,018





    $       (12,497,629)



    $                      -







    Cash flows from investing activities:

    $                      -







    Purchase of property, plant and equipment

    $        (247,347)





    $               181,808

    Capitalized costs for patents

    $        (156,349)





    $                          -

    Investment in joint venture

    $        (765,000)





    $            (767,285)

    Net cash used in investing activities

    $     (1,168,696)





    $            (585,477)



    $                      -







    Cash flows from financing activities:

    $                      -







    Common stock repurchase

    $                      -





    $              (60,488)

    Proceeds from long term debt

    $                      -





    $            2,339,362

    Repayment of borrowing

    $        (319,004)





    $                           -

    Net cash used in financing activities

    $        (319,004)





    $            2,278,874



    $                       -







    Net increase in cash

    $           468,318





    $       (10,804,232)

    Cash – beginning of period

    $      17,615,334





    $          34,395,386

    Cash and restricted cash– end of period

    $      18,083,652





    $          23,591,154

    Reconciliation of cash and restricted cash









    Cash

    $      18,033,652





    $          23,518,560

    Restricted cash

    $             50,000





    $                 72,594

    Total cash and restricted cash

    $      18,083,652





    $          23,591,154

    Supplemental non-cash investing and financing activities









    Reclassification of accounts receivable – noncurrent to accounts receivable

    $                      -





    $                          -

    Reclassification of accounts payable – related party to amount due to a

    related party

    $        6,000,000





    $                          -

    Leased assets obtained in exchange for operating lease liabilities

    $                      -





    $            2,771,082

    Unpaid long term investment in accrued liabilities and other payables

    $                      -





    $            8,232,715

    Supplemental disclosures

    $                      -





    $                          -

    Cash paid for income taxes

     $                  3,081    -  





    $                           -

    Cash paid for interest

    $             87,215





    $                 35,646

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ispire-technology-inc-reports-financial-results-for-fiscal-third-quarter-2026-302764809.html

    SOURCE Ispire Technology Inc.

    Get the next $ISPR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ISPR

    DatePrice TargetRatingAnalyst
    5/20/2024$11.00Buy
    ROTH MKM
    More analyst ratings

    $ISPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Fargis John

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    3/19/26 4:02:32 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Cox Brent

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    3/19/26 4:02:12 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Burch Christopher Robert

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    3/19/26 4:01:47 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ispire Technology Inc. Reports Financial Results for Fiscal Third Quarter 2026

    Cash Increased Sequentially by $468,000 to $18 MillionPlans to Achieve Cash Flow Positive in Second Half of Calendar Year 2026 Business Stabilized Following Strategic RepositioningPhased Roadmap Targets Billions in Addressable Market, Including ~$73B Global Vape, ~$50–70B U.S. Flavored Vape, and $24B+ Global G-Mesh Glass TechnologyLOS ANGELES, May 7, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the third quarter of fiscal 2026, for the three months ended March 31, 2026.

    5/7/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal Third Quarter 2026 Earnings Conference Call

    LOS ANGELES, May 1, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Thursday, May 7, 2026, to discuss the Company's financial results for its fiscal third quarter ended March 31, 2026. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call."Date: Thursday, May 7, 2026Time: 8:00 am ETDial-In Numbers: United Stat

    5/1/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    IKETech Wins "Privacy-Centric Age Assurance Solution of the Year," Recognized for Innovation at Global Industry Awards

    Dual honors at GAAS Summit underscore growing regulatory and commercial validation for IKETech's point-of-use, privacy-first compliance platformLOS ANGELES, April 23, 2026 /PRNewswire/ -- IKETech LLC, an AI-powered compliance infrastructure company and joint venture among Ispire Technology Inc. (NASDAQ: ISPR), Berify, and Chemular Inc., announced it has received dual recognition at the Age Assurance Industry Awards 2026, presented at the Global Age Assurance Standards Summit (GAAS) in Manchester, UK. The company was named Winner of "Privacy-Centric Age Assurance Solution of the

    4/23/26 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    SEC Filings

    View All

    SEC Form DEFA14A filed by Ispire Technology Inc.

    DEFA14A - Ispire Technology Inc. (0001948455) (Filer)

    5/12/26 4:31:15 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form DEF 14A filed by Ispire Technology Inc.

    DEF 14A - Ispire Technology Inc. (0001948455) (Filer)

    5/12/26 4:30:34 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Ispire Technology Inc.

    10-Q - Ispire Technology Inc. (0001948455) (Filer)

    5/7/26 4:31:19 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Wang Michael Xue bought $11,959 worth of shares (5,000 units at $2.39), increasing direct ownership by 1% to 466,882 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    3/2/26 4:58:37 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Co-Chief Executive Officer Wang Michael Xue bought $18,529 worth of shares (8,000 units at $2.32), increasing direct ownership by 2% to 461,882 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    2/26/26 4:27:49 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Ispire Technology with a new price target

    ROTH MKM initiated coverage of Ispire Technology with a rating of Buy and set a new price target of $11.00

    5/20/24 7:18:59 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Leadership Updates

    Live Leadership Updates

    View All

    WM Technology, Inc. Appoints Harry DeMott and Brent Cox to Board of Directors and Announces Executive Employment Arrangement with CFO Susan Echard

    WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Harry DeMott and Brent Cox to the Company's Board of Directors, effective February 1, 2026. The Company also announced that Susan Echard will continue to serve as Chief Financial Officer, transitioning from a contracted arrangement to employment with the Company, effective January 30, 2026. "We are pleased to welcome Harry and Brent to WM Technology's Board of Directors. They each bring a combination of cannabis industry perspective, technology fluency, and disciplined capital markets experience," said Do

    2/3/26 5:45:00 PM ET
    $ISPR
    $MAPS
    Medicinal Chemicals and Botanical Products
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Ispire-Backed IKE Tech to Spotlight Breakthroughs in Vape Safety and Harm Reduction at World Vape Show Dubai

    President of Ike Tech and SVP of International Nicotine at Ispire, John Patterson, to Join Global Leaders on Industry Innovation Panel LOS ANGELES, June 16, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a global leader in vaporization technology and precision dosing, announced its joint venture IKE Tech LLC ("IKE Tech") will spotlight Ike Tech's blockchain based point of use age-gating and Smart-Tag authentication technologies at the World Vape Show Dubai, June 18–20, 2025. John Patterson, president of Ike Tech and senior vice president of International Nicotine at Ispire, will be featured on a high-level panel titled "Innovations in Consumer Safety

    6/16/25 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Announces Appointment of Jay Yu as Chief Financial Officer

    Jie "Jay" Yu has a strong track record of excellence in public company accounting, and has served in the role of Vice President of Finance for Ispire since June 2023 Ispire also further streamlines operations by cutting an estimated $3.6 million in annual payroll in May 2025 Ispire expects to also cut up to an additional $6.6 million in annual operating expenses over the next three months, for a total estimated annualized expense reduction of $10.2 million LOS ANGELES, May 15, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced the appointment of Jie "Jay" Yu as the

    5/15/25 4:30:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Financials

    Live finance-specific insights

    View All

    Ispire Technology Inc. Reports Financial Results for Fiscal Third Quarter 2026

    Cash Increased Sequentially by $468,000 to $18 MillionPlans to Achieve Cash Flow Positive in Second Half of Calendar Year 2026 Business Stabilized Following Strategic RepositioningPhased Roadmap Targets Billions in Addressable Market, Including ~$73B Global Vape, ~$50–70B U.S. Flavored Vape, and $24B+ Global G-Mesh Glass TechnologyLOS ANGELES, May 7, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the third quarter of fiscal 2026, for the three months ended March 31, 2026.

    5/7/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal Third Quarter 2026 Earnings Conference Call

    LOS ANGELES, May 1, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Thursday, May 7, 2026, to discuss the Company's financial results for its fiscal third quarter ended March 31, 2026. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call."Date: Thursday, May 7, 2026Time: 8:00 am ETDial-In Numbers: United Stat

    5/1/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2026

    Ongoing Focus on Collections Drives 19% Reduction in Net Accounts Receivable since June 30, 2025Cash of $17.6 Million at December 31, 2025  LOS ANGELES, Feb. 6, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the second quarter of fiscal 2026, for the three months ended December 31, 2025. Fiscal Second Quarter 2026 Financial Results Revenue of $20.3 million versus $41.8 million for the second quarter of fiscal 2025.Gross profit

    2/6/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ispire Technology Inc.

    SC 13G - Ispire Technology Inc. (0001948455) (Subject)

    7/12/24 5:00:02 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care